🏥 Pharma Stocks in Spotlight: Sun Pharma, Cipla & Dr. Reddy’s - Play bazaar

 

🏥 Pharma Stocks in Spotlight: Sun Pharma, Cipla & Dr. Reddy’s play bazaar

📊 Share Price Snapshot — Sun Pharma

• Sun Pharma is trading around ₹1,586.70 (down ~2.50%) on the NSE today. Groww+2Reuters+2

  play bazaar

• Its 52-week range: ₹1,548 – ₹1,960.35 Moneycontrol+1c  

  play bazaar

• Key fundamentals:
  • Market cap: ~ ₹3,80,666 crore (or ~ ₹3,80,315 cr as per different sources) Screener+1
  • P/E ratio (TTM): ~ 37–38× Reuters+2Screener+2 

  play bazaar

  • ROE / ROCE are healthy; debt is low. Screener

I couldn’t immediately find reliable live prices for Cipla or Dr. Reddy’s in my search, but they move similarly in response to sectoral news, so they’ll likely be under pressure today.  

play bazaar

---

🌩️ Trump’s 100% Pharma Tariff: What’s the Big Deal?

What Trump Announced

• Starting October 1, 2025, the U.S. will impose a 100% tariff on branded & patented pharmaceuticals imported into the U.S., unless the company is building (or has begun building) manufacturing facilities in the U.S. Al Jazeera+3The Indian Express+3The Economic Times+3 

  play bazaar

• Trump also introduced tariffs on other goods: trucks, furniture, etc., but the pharma tariff is by far the most headline-grabbing given India’s export exposure. Al Jazeera+2The Economic Times+2 

  play bazaar

Why It Hits India’s Pharma Sector

• India is a major supplier of generics, active pharmaceutical ingredients, and some branded drugs to the U.S. 

  play bazaar

• While many Indian companies focus on generics (which might be exempt or less impacted), the announcement raises uncertainty: will complex generics, biosimilars, or partial “patented / branded” products also be caught in the tariff net? www.ndtv.com+2Moneycontrol+2  

  play bazaar

• Stocks dived sharply today: the Indian pharma sector lost ~2.4–2.6%, and leading names like Sun Pharma saw ~3–5% drops. The Times of India+4Reuters+4Reuters+4

• Some analysts point out that the impact might be mitigated if companies can locate or expand manufacturing in the U.S., or if the tariff applies selectively. The Economic Times+3The Indian Express+3www.ndtv.com+3 

  play bazaar

---

🔍 Which Pharma Stocks Are Most Vulnerable?

• Dr. Reddy’s is considered one of the more vulnerable names because of its exposure to specialty / branded / patented products in the U.S. The Economic Times 

  play bazaar

• Sun Pharma is somewhat cushioned by its generics mix, but it has branded / specialty portfolios that could suffer. www.ndtv.com+3The Economic Times+3Reuters+3 

  play bazaar

• Cipla may be less exposed to patented drug business (relatively), so analysts believe its downside from this specific tariff may be lesser. The Economic Times+1 

  play bazaar

---

📌 What Investors Should Watch & Strategy Thoughts

• Clarification on scope: Exactly how “branded / patented” vs “generic / biosimilar” are defined in the U.S. regulation will matter a lot. If many drugs are spared, damage is limited. 

  play bazaar

• Manufacturing moves: If Indian pharma firms can accelerate U.S. manufacturing or get “under construction” status quickly, they may be exempt. 

  play bazaar

• Cost restructuring: Firms may shift product mix away from vulnerable products or absorb part of tariff via margins. 

  play bazaar

• Short-term volatility: Expect more stock swings. Some capitulation selling may happen. 

  play bazaar

• Watch competitor & sector moves: Others in pharma or global peers will also react; see which adapt fastest. 

  play bazaar